Status:
UNKNOWN
N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
Lead Sponsor:
Cairo University
Collaborating Sponsors:
Kasr El Aini Hospital
Conditions:
COVID19 Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to assess the difference between level of NT-pro-BNP, and Vitmin D in moderate cases who progressed to severe or critically ill category compared to those who did not. Assessme...
Detailed Description
On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. An acute respiratory disease, caused by a novel cor...
Eligibility Criteria
Inclusion
- All cases will be diagnosed with COVID-19 by RT-PCR • Group (1) Critically ill patients: Respiratory Rate \> 30/min SaO2 \< 92% at room temperature Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours • Group (2) moderate cases: Patients has pneumonia manifestations on radiology associated with symptoms \&/or leucopenia or lymphopenia.
Exclusion
- Other causes of pneumonia other than infection with SARS-CoV-2.
- Concomitant heart failure.
- Hypoxic patients on hospital admission.
- Arrhythmia.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04487951
Start Date
July 1 2020
End Date
January 1 2021
Last Update
July 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr Alainy Cairo University
Cairo, Giza Governorate, Egypt, 11562